3,967 Ascendis Pharma A/S $ASND Shares Acquired by Sigma Planning Corp

Sigma Planning Corp grew its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 173.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,257 shares of the biotechnology company’s stock after buying an additional 3,967 shares during the quarter. Sigma Planning Corp’s holdings in Ascendis Pharma A/S were worth $1,426,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. Personal CFO Solutions LLC grew its holdings in Ascendis Pharma A/S by 4.4% during the first quarter. Personal CFO Solutions LLC now owns 1,519 shares of the biotechnology company’s stock worth $347,000 after acquiring an additional 64 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in Ascendis Pharma A/S by 34.0% in the first quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 69 shares during the period. Allworth Financial LP lifted its holdings in Ascendis Pharma A/S by 103.4% in the second quarter. Allworth Financial LP now owns 240 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 122 shares during the period. Parallel Advisors LLC lifted its holdings in Ascendis Pharma A/S by 94.9% in the first quarter. Parallel Advisors LLC now owns 304 shares of the biotechnology company’s stock valued at $70,000 after acquiring an additional 148 shares during the period. Finally, IFP Advisors Inc boosted its position in shares of Ascendis Pharma A/S by 54.8% during the 3rd quarter. IFP Advisors Inc now owns 667 shares of the biotechnology company’s stock worth $152,000 after purchasing an additional 236 shares in the last quarter.

Insider Buying and Selling

In related news, SVP Mads Bodenhoff sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total transaction of $810,570.00. Following the completion of the transaction, the senior vice president owned 3,000 shares in the company, valued at $810,570. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jean-Jacques Bienaimé acquired 2,000 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were bought at an average price of $246.33 per share, with a total value of $492,660.00. Following the completion of the purchase, the director owned 2,900 shares in the company, valued at $714,357. The trade was a 222.22% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 40.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ASND. Wall Street Zen raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research note on Saturday, October 10th. Bank of America lowered their target price on shares of Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating on the stock in a research report on Monday, August 31st. Canaccord Genuity Group set a $268.00 target price on shares of Ascendis Pharma A/S in a research report on Monday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Ascendis Pharma A/S in a research note on Tuesday, October 13th. Finally, TD Cowen reissued a “buy” rating on shares of Ascendis Pharma A/S in a report on Thursday, September 10th. Nineteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $305.95.

Ascendis Pharma A/S Stock Performance

Shares of ASND stock opened at $249.55 on Thursday. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. The business has a 50 day moving average of $242.51 and a two-hundred day moving average of $237.55. Ascendis Pharma A/S has a 52 week low of $188.07 and a 52 week high of $282.15. The company has a market cap of $15.57 billion, a P/E ratio of 19.36 and a beta of 0.38.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). The company had revenue of $387.22 million for the quarter, compared to the consensus estimate of $376.75 million. Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. As a group, analysts anticipate that Ascendis Pharma A/S will post 3.43 EPS for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve treatment convenience, maintain controlled drug exposure, and address unmet medical needs.

Its commercial products include SKYTROFA (lonape­gsomatropin-tcgd), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a once-daily therapy for adults with hypoparathyroidism.